2seventy bio (TSVT) Stock Price, News & Analysis

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for 2seventy bio in the last twelve months. There are currently 5 hold ratings, 4 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" TSVT shares.
View TSVT analyst ratings or view top-rated stocks.

10 Wall Street analysts have issued 12-month price targets for 2seventy bio's shares. Their TSVT share price targets range from $5.00 to $26.00. On average, they anticipate the company's share price to reach $12.86 in the next twelve months. This suggests a possible upside of 167.9% from the stock's current price.
View analysts price targets for TSVT or view top-rated stocks among Wall Street analysts.

2seventy bio's stock was trading at $4.27 at the beginning of 2024. Since then, TSVT stock has increased by 12.4% and is now trading at $4.80.
View the best growth stocks for 2024 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024.
View our TSVT earnings forecast.

2seventy bio, Inc. (NASDAQ:TSVT) posted its quarterly earnings results on Tuesday, March, 5th. The company reported ($1.11) earnings per share for the quarter, beating the consensus estimate of ($1.22) by $0.11. The company earned $10.68 million during the quarter, compared to analyst estimates of $13.91 million. 2seventy bio had a negative trailing twelve-month return on equity of 67.59% and a negative net margin of 313.51%. During the same quarter in the previous year, the firm posted ($0.60) EPS.

ETFs with the largest weight of 2seventy bio (NASDAQ:TSVT) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA), Range Cancer Therapeutics ETF (CNCR), Loncar China Biopharma ETF (CHNA) and Horizon Kinetics Medical ETF (MEDX).Global X Genomics & Biotechnology ETF (GNOM).

2seventy bio's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (7.26%), Healthcare of Ontario Pension Plan Trust Fund (3.38%), Jacobs Levy Equity Management Inc. (0.74%), Susquehanna Fundamental Investments LLC (0.27%), Wedmont Private Capital (0.17%) and Price T Rowe Associates Inc. MD (0.06%). Insiders that own company stock include Casdin Capital, Llc, Jessica Snow, Kynam Capital Management, Lp, Nick Leschly, Nicola Heffron, Philip D Gregory and William D Baird III.
View institutional ownership trends.

Shares of TSVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.